ELVN-001
Phase 1Recruiting 0 watching 0 views this week๐ค Quiet
28
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
CML (Chronic Myelogenous Leukemia)
Conditions
CML (Chronic Myelogenous Leukemia), Chronic Phase CML
Trial Timeline
Jan 23, 2025 โ Jan 1, 2028
NCT ID
NCT06787144About ELVN-001
ELVN-001 is a phase 1 stage product being developed by Enliven Therapeutics for CML (Chronic Myelogenous Leukemia). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06787144. Target conditions include CML (Chronic Myelogenous Leukemia), Chronic Phase CML.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06787144 | Phase 1 | Recruiting |
| NCT05304377 | Phase 1 | Recruiting |
Competing Products
5 competing products in CML (Chronic Myelogenous Leukemia)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 85 |
| BGF MDI 320/14.4/9.6 ฮผg + GFF MDI 14.4/9.6 ฮผg | AstraZeneca | Phase 3 | 77 |
| BGF MDI HFO 320/14.4/9.6ฮผg + BGF MDI HFA 320/14.4/9.6 ฮผg + Placebo MDI HFA | AstraZeneca | Phase 3 | 77 |
| Inhaled Treprostinil (Tyvaso Nebulizer) | United Therapeutics | Phase 2 | 49 |
| umeclidinium 62.5 ยตg and vilanterol 25 ยตg + Revefenacin 175 ยตg, Formoterol 20 ยตg + Placebo ( Revefenacin and Formoterol ) + Placebo DPI | Theravance Biopharma | Approved | 80 |